Video

Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

Pieter Sonneveld, MD, PhD, Head of the Department of Hematology, Erasmus University Medical Center, discusses the SKY92 prognostic indicator (MMPROFILER) for multiple myeloma.

Sonneveld and his team collected the DNA of tumors cells of more than 350 newly diagnosed patients with multiple myeloma. They then worked to identify which genes were overactive in the tumor cells of those patients and did a principal component analysis to find out what the most important genes that are relevant for the prognosis of those patients.

Ninety-two genes were identified that represent important pathways in multiple myeloma biology, says Sonneveld. Based on this data, a tool was created that can be used to predict the prognosis of individual myeloma patients or cohorts of patients in large clinical trials.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD